On the other hand, previous studies have reported that enhanced AXL expression is often associated with acquired resistance to osimertinib in lung cancer cells21,22, and also that enhanced expression of both AXL and CDCP1 is associated with poor outcomes of patients with NSCLC23. This evidence concerns the gene CDCP1 and lung cancer.